Masitinib scientific data 22/09/2011 – for veterinary medicine n°3 The Veterinary Journal 21/02/2011 – Results from a preclinical study showing that masitinib has potential as a chemosensitizer Masitinib in Mast Cell Tumor – Phase 3 data 02/11/2010 – Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors VCS Summer Newsletter 01/07/2010 – Masitinib – The Efficacy of Targeted therapy in Veterinary Medicine Veterinary Research Communications 16/06/2009 – Pharmacokinetics of masitinib in cats. ESVONC 2009 29/03/2009 – Evaluation of masitinib in the treatment of canine mast cell tumors: Long-term follow-up efficacy data from phase III clinical study. ESVONC 2009 26/03/2009 – Assessment of response to the treatment with masitinib (Masivet) of chemotherapy resistant, grade 2 and 3, metastasized canine cutaneous mast cell tumors. J Vet Intern Med 22/11/2008 – Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. 2008 VCS Annual Conference 21/10/2008 – Masitinib as a chemosensitizer of canine tumor cell lines. Mol Cancer Res. 21/07/2008 – Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors International Veterinary Information Service 17/09/2006 – A novel c-Kit inhibitor (AB1010) shows therapeutic potential in dog mast cell tumors. Post navigationPreviousPrevious post:Veterinary Medicine – Inflammatory diseasesNextNext post:Human Medicine – Central Nervous System DiseasesRelated PostsHuman Medicine – OncologyJuly 1, 2016Mast Cells as a TargetJanuary 21, 2015Basic ResearchJuly 25, 2014Human Medicine – Central Nervous System DiseasesApril 26, 2014Veterinary Medicine – Inflammatory diseasesJanuary 1, 2010
